During their recent earnings call, RVL Pharmaceuticals (NASDAQ: RVLP) reported Q4 2021 revenue of $2.86 million up 151.98% year over year. Their unique product, Upneeq, is the ONLY FDA-approved prescription eye drop for acquired ptosis (low-lying lids) that lifts your upper eyelids to open your eyes.
RVLP was previously named OSMT and after divesting from its legacy business (generic prescriptions) it pivoted into the aesthetics/eye-care market. It's a great time to invest, as the stock is sitting around $1.70 (up over 50% in the last months) with plenty of room for (projected) exponential growth. Check out more at r/rvlp
Leave a Reply